IHC

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Thursday, October 21, 2021 - 1:31pm

Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.
  • 1 Together with cancers of the gastroesophageal junction, they constitute an important and growing global health concern.
  • PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO (nivolumab).
  • CA: A Cancer Journal for Clinicians, 71(3), 209249. https://doi.org/10.3322/caac.21660
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005619/en/

JAB Expands Pet Insurance Platform Through Acquisition of Figo Pet Insurance

Wednesday, October 20, 2021 - 6:14pm

JAB is pleased to announce that Independence Pet Holdings (formerly Iguana Capital), JABs U.S. pet insurance platform, has entered into a definitive agreement to acquire Figo, one of the leading U.S. providers of pet insurance.

Key Points: 
  • JAB is pleased to announce that Independence Pet Holdings (formerly Iguana Capital), JABs U.S. pet insurance platform, has entered into a definitive agreement to acquire Figo, one of the leading U.S. providers of pet insurance.
  • Todays news follows the recently announced acquisition of Independence Holding Companys (IHC) pet insurance business, which includes the consumer-facing PetPartners, and IHCs pet insurance underwriting business, Independence American Insurance Company (Independence American).
  • Independence Pet Holdings is an integrated, full-stack pet insurance platform owned by JAB Holding Company (JAB) and Independence Holding Company (IHC).
  • It is also a majority shareholder in Pet Partners, Inc., which owns world-class pet insurance brands such as AKC Pet Insurance and PetPartners.

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

Wednesday, October 13, 2021 - 9:16pm

This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly and Company.

Key Points: 
  • This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly and Company.
  • Conventional methods for evaluating the risk of recurrence in EBC are based on staging and are performed according to standard clinical and pathological features of the disease.
  • However, these standard features may not capture the full risk of recurrence for individuals with EBC.
  • The American Joint Committee on Cancer has identified the Ki-67 biomarker as Level of Evidence III in diagnosing EBC due to its association with cellular proliferation.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

Tuesday, October 12, 2021 - 12:00pm

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2021 and provided a business update on recent corporate and operational developments.

Key Points: 
  • In November 2020, Enzo announced the appointment of Ian B. Walters, MD, and Mary Tagliaferri, MD, to the Board of Directors.
  • Enzo Life Sciences (ELS) fiscal 2021 revenues amounted to $30.7 million, up 16% from fiscal 2020.
  • Total fourth quarter revenues were $24.8 million, an increase of 27% from $19.5 million in the fourth quarter last year, but a decrease of 24% sequentially.
  • Enzo Clinical Lab revenue increased 30% to $16.8 million from $12.9 million in the fourth quarter 2020.

Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

Thursday, October 7, 2021 - 5:50pm

We look forward to providing additional clinical data on BT5528 and BT8009 next year, and initiating our Phase I/II study for BT7480 later this year.

Key Points: 
  • We look forward to providing additional clinical data on BT5528 and BT8009 next year, and initiating our Phase I/II study for BT7480 later this year.
  • BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful, has demonstrated preliminary anti-tumor activity.
  • Doses of BT5528 administered to date have been tolerated in the ongoing Phase I portion of the Phase I/II trial.
  • ET to review the BT5528 trial data being presented at the AACR-NCI-EORTC meeting and provide an update on preliminary findings from the BT8009 trial.

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

Thursday, October 7, 2021 - 1:55pm

Patients are continuing to enroll in the expansion cohort and we look forward to reporting an update from the Phase 1b trial in 2022.

Key Points: 
  • Patients are continuing to enroll in the expansion cohort and we look forward to reporting an update from the Phase 1b trial in 2022.
  • Enrollment continues in the Part II dose expansion cohorts at nine clinical sites across the United States.
  • Based on preclinical and clinical studies, ORIC-101 is expected to have reduced drug-drug interaction liabilities than other glucocorticoid receptor antagonists.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.

Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Thursday, October 7, 2021 - 2:00pm

This is representative of our commitment to emerge as a leader in targeted radionuclide therapy by developing innovative radiotherapies such as FAP-2286 for patients with hard-to-treat cancers.

Key Points: 
  • This is representative of our commitment to emerge as a leader in targeted radionuclide therapy by developing innovative radiotherapies such as FAP-2286 for patients with hard-to-treat cancers.
  • To determine FAP protein expression in different tumor types, a pan-tumor IHC screen was performed that included 360 samples representing 16 different tumor types.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).
  • LuMIERE is a Phase 1/2 study evaluating FAP-2286 as a peptide-targeted radionuclide therapy (PTRT) targeting fibroblast activation protein, or FAP, in patients with advanced solid tumors (NCT04939610) .

CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

Thursday, October 7, 2021 - 10:48am

The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.

Key Points: 
  • The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.
  • "Everyone here at CerbACT Asia is fully committed to provide high-quality results to our clients and hope to improve patient outcomes through precision medicine," says Dr George Wei, Managing Director of CerbACT Asia.
  • Together, we offer a broader range of top-notch technologies and services in Asia.
  • CerbACT Asia is an Immuno-Oncology Centre of Excellence that empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research and clinical development strategies.

Inflation Hedging Coin (IHC) Introduces DeFi Solution to Inflation in Mongolia

Thursday, October 7, 2021 - 11:00am

A novel crypto-asset recently launched from Mongolia aims to provide a buffer against inflation.

Key Points: 
  • A novel crypto-asset recently launched from Mongolia aims to provide a buffer against inflation.
  • View the full release here: https://www.businesswire.com/news/home/20211007005491/en/
    Copyrights by Inflation Hedging Coin (IHC) (Photo: Business Wire)
    The crypto project, the brainchild of a consortium of native tech-preneurs, focuses on burning tokens or permanently removing them to cut down the rate of inflation and increase the value of the asset.
  • In addition, the U.S. House of Representatives is currently wrestling with the implications of increasing the debt ceiling beyond $28.4tn.
  • There are already early signs of local inflation in many parts of the world, threatening the purchasing power of many households.

T-Cure Bioscience, Inc. and Atlas Antibodies AB Enter a Collaboration Agreement for the Development, Manufacture, and Supply of CT83 (KK-LC-1) Monoclonal Antibodies

Tuesday, October 5, 2021 - 8:01am

Patients with KK-LC-1 positive tumors may be eligible for inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.

Key Points: 
  • Patients with KK-LC-1 positive tumors may be eligible for inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.
  • Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development.
  • T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsored clinical trial planned for 2022.
  • Headquartered in Stockholm, Sweden, Atlas Antibodies provides high-quality reagents for biomedical research, including polyclonal and monoclonal antibodies and QPrESTs.